Compare VMI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMI | ERAS |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | 10791 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.3B |
| IPO Year | 1994 | 2021 |
| Metric | VMI | ERAS |
|---|---|---|
| Price | $385.66 | $13.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $610.75 | $25.10 |
| AVG Volume (30 Days) | 162.5K | ★ 5.1M |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 17.88 | N/A |
| Revenue | ★ $3,169,556,000.00 | N/A |
| Revenue This Year | $6.09 | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | $22.93 | ★ N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $379.28 | $2.81 |
| 52 Week High | $585.71 | $24.28 |
| Indicator | VMI | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 42.80 |
| Support Level | N/A | $13.18 |
| Resistance Level | $487.35 | $15.71 |
| Average True Range (ATR) | 13.46 | 1.31 |
| MACD | -0.86 | -0.13 |
| Stochastic Oscillator | 2.31 | 14.12 |
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting, transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.